NewBiologix Launches Next-Generation Sequencing and Optical Mapping Platform to Drive the Next Wave of Biopharmaceutical Discoveries
30 Abril 2024 - 7:00AM
Business Wire
NewBiologix SA, a technology innovation company focused on
addressing gene therapy manufacturing gaps, announced the launch of
its next-generation sequencing (NGS) and optical mapping platform,
a novel suite of technologies combined to offer comprehensive
genomic analysis services to the biopharmaceutical industry.
This platform integrates the latest advancements in sequencing
and genomic mapping technologies, combining the strengths of
industry leaders such as Illumina, PacBio, Nanopore, and Bionano.
The result is versatile platform capable of addressing the complex
demands of genomic research.
Igor Fisch, Ph.D., NewBiologix CEO and Co-founder, said:
“NewBiologix allows customers to have access accurate and
high-fidelity sequencing data generated by a state-of-the-art
platform without having to navigate the complexities of sequencing
technologies using different sequencing providers.”
The thorough and precise preparation of samples is critical in
achieving reliable, high-quality data from next-generation
sequencing, which in turn supports robust scientific conclusions.
At the heart of NewBiologix's platform lies a commitment to
excellence in sample preparation and library construction.
NewBiologix ensures every sample is meticulously handled to produce
high-quality results for researchers across diverse domains.
Thierry Schuepbach, NewBiologix CDO, said: “NewBiologix’s
commitment to innovation and Swiss quality ensures our customers
receive meaningful data that can accelerate research and
development processes. Our integrated approach to sequencing and
mapping allows for a deeper understanding of genomic, epigenetic,
and transcriptomic landscapes, which is critical for the
advancement next-generation therapeutics.”
Key advantages of NewBiologix's platform include:
- Advanced Sequencing Technologies: Leveraging the power
of short reads (Illumina) and long reads (PacBio and Nanopore),
NewBiologix offers high-fidelity and meaningful sequencing to meet
the diverse needs of genomic research.
- Optical Mapping Expertise: Through state-of-the-art
Bionano Saphyr optical mapping technology, NewBiologix bridges gaps
in sequence information, facilitating accurate genome assembly and
analysis.
- Expert Sample Preparation: Success on any
next-generation sequencing platform begins with optimal sample
preparation and library construction. NewBiologix's team of experts
ensures that each sample is handled with precision and care,
resulting in high-quality sequencing data.
- Customized Services: NewBiologix offers customized
services tailored to each project’s specific requirements. Whether
assisting in technology selection, optimizing sample multiplexing
or maximizing coverage, NewBiologix provides customized solutions
to drive success.
- High Responsivity and Short Turnaround: Focusing on
customer satisfaction, NewBiologix delivers rapid, responsive
services with short turnaround times. Researchers can expect timely
results while maintaining quality and accuracy.
For more information about NewBiologix and its next-generation
sequencing and optical mapping platform, please visit
newbiologix.com.
About NewBiologix:
Based in Lausanne, Switzerland, NewBiologix SA is a technology
innovation company focused on developing a proprietary platform for
the advanced engineering of cells lines for the generation and
production of viral vectors used in gene and cell therapies. By
combining an innovative and proprietary genomic analysis platform
with advanced R&D experimentation, the company’s mission is to
help biopharmaceutical companies develop transformative gene
therapies faster, safer and at scale. Learn more at
www.newbiologix.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430339483/en/
Corporate Contact: Deborah Ley Chief Operating Officer
deborah.ley@newbiologix.com